Receipt of a significant order by a subsidiary of Selvita S.A.
The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”), hereby announces that the company affiliated with the Issuer Selvita Services Sp. z o.o. with its registered office in Krakow, received on the September 1st, 2023 an order from a biopharmaceutical company based in Europe (“Client”), the subject of which is to conduct analyses of samples derived from the biologic drug purification process. These analyses serve as essential characterization and validation of activities aimed at confirming that the utilized production process is proper at all stages and will lead to a specific product profile in terms of its quality (“Order”). Analyses within the scope of the Order will be carried out over the course of 8 months.
The value of the Order will range from EUR 2,400,368 to EUR 3,600,552 depending on the number of analyses performed, which equates to PLN 10,744,527.24 to PLN 16,116,790.86 when converted at the average exchange rate of the National Bank of Poland on September 1st, 2023, where 1 EUR = 4.476 PLN.
The Issuer’s collaboration with the Client has been ongoing since 2018, and the Order is the largest project undertaken so far by the Issuer for the Client. Considering the value of the project, the Issuer’s Management Board deems the Order to be significant.
Legal basis: Art. 17.1 of MAR
Representatives of the Issuer:
- Miłosz Gruca – Vicepresident of the Management Board
- Dawid Radziszewski – Management Board Member